Full-Time
Senior Software Engineer
Updated on 3/14/2025
GRAIL
1,001-5,000 employees
Develops blood tests for early cancer detection
No salary listed
Senior
London, UK
Candidates must be within easy commute of central London.
- Bachelor's or Master's degree in Computer Science, Mathematics, Electrical Engineering, Bioinformatics or a similar technical field or equivalent
- 5+ years of relevant work experience designing, developing, testing and maintaining software
- Familiar with at least one general purpose programming language such as Go, Java or TypeScript
- Experience working on cloud platforms such as AWS, GCP, or Microsoft Azure
- Excellent logical reasoning and analytical skills, with a preference for simple solutions
- Strong written and verbal communicator who can adapt communication style and level of detail to the audience
- Use your experience developing full-stack applications to build software that supports cancer research
- Build and operate the infrastructure and tooling that runs the systems and powers the team
- Work as part of a cross-functional team to overcome real-world problems that sometimes can’t be solved with software alone
- Work on systems which are built in Go, Java, React & MySQL
- Experience with healthcare or biotech systems is a plus
- You are within easy commute of central London, this is a hybrid role
GRAIL focuses on improving cancer detection through advanced blood tests that identify cancer at its earliest stages, enhancing treatment success rates. The company utilizes high-intensity sequencing to analyze tumor genome data, employing algorithms and deep learning to extract actionable information for early cancer detection. GRAIL differentiates itself from competitors by its commitment to large-scale clinical studies that validate the effectiveness of its tests. The primary goal is to reduce global cancer mortality by enabling early diagnosis, making the disease more treatable.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
$9.8B
Headquarters
Menlo Park, California
Founded
2016
Simplify's Take
What believers are saying
- Collaboration with Function Health expands GRAIL's market reach and test adoption.
- Publication in Lancet Oncology boosts GRAIL's credibility and professional acceptance.
- Separation from Illumina allows GRAIL to pursue aggressive growth strategies.
What critics are saying
- Potential overdiagnosis of indolent cancers could lead to unnecessary treatments.
- Significant net loss raises concerns about GRAIL's financial sustainability.
- Separation from Illumina may present operational challenges and require adjustments.
What makes GRAIL unique
- GRAIL uses high-intensity sequencing for early cancer detection, setting it apart.
- The Galleri test screens for over 50 cancers with a single blood draw.
- GRAIL's tests focus on detecting aggressive cancers, minimizing overdiagnosis risks.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Outstanding People - Join a team of passionate and dedicated professionals, committed to collaboration, education, and proactive problem-solving.
Strong Compensation - We offer competitive salaries and savings plans to provide for long-term financial planning.
Complete Health Coverage - Take advantage of comprehensive health coverage, with medical, dental and vision, to keep you and your family healthy.
Work-Life Balance - Make everyday life more manageable with flexible time off – we trust you to do great work and take time for yourself.
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 2%2 year growth
↑ 2%MENLO PARK, Calif., Feb. 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, Mar. 4 at 9:10 a.m. ET.Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection TestingMENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included secondary and exploratory outcomes with the objective of assessing PRO and perceptions of multi-cancer early detection (MCED) testing.PRO assessment was conducted for eligible PATHFINDER study participants with either a cancer signal detected (CSD) or no cancer signal detected (NCSD) over a 12-month follow-up period. In the PATHFINDER study, general anxiety, distress and uncertainty after results disclosure, health-related quality of life, satisfaction with the Galleri® test, and intent towards guideline-recommended screening and repeat MCED testing were assessed. Three instruments used to assess PRO included an adapted Multidimensional Impact of Cancer Risk Assessment (MICRA) for distress, uncertainty and positive experience at MCED test result disclosure, PRO Measurement Information System (PROMIS) Anxiety short-form for anxiety symptoms, the Short Form 12-Item Health Survey (SF-12v2) for health-related quality of life, and a satisfaction questionnaire."Previous studies have shown that there is a temporary increase in anxiety symptoms after cancer screening, particularly for those with a test result indicating they may have cancer," said Lincoln Nadauld, MD, lead author of the study and was vice president, chief of Precision Health & Academics at Intermountain Health during the PATHFINDER study and currently CEO at Culmination Bio, Inc
MENLO PARK, Calif., Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15 at 9:00 a.m. PT.Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com
Function Health has partnered with cancer test startup GRAIL.
What You Should Know:– Function Health, a revolutionary health management platform empowering people to live 100 healthy years, announces a collaboration with GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, to expand the reach of innovative cancer screening to transform cancer care.– Function Health’s 400,000+ members nationwide have access to GRAIL’s Galleri test—a first-of-its-kind, clinically validated multi-cancer early detection (MCED) test that screens for multiple cancers with a simple blood draw—as an add-on to its comprehensive list of 100+ lab tests.Function Health: Revolutionizing Preventative Care with Comprehensive Lab Testing and Early Cancer DetectionFunction Health is a pioneering health platform offering access to over 100 lab tests, enabling individuals to gain comprehensive insights into their overall health—including heart health, hormones, thyroid function, nutrients, toxins, immunity, and autoimmune markers. At $499 annually, the platform provides five times more testing than the average physical, which typically assesses only 19 biomarkers. Unlike traditional methods, it eliminates hidden costs, surprise bills, and insurance complications.A Groundbreaking Approach to Early Cancer DetectionFunction Health has partnered with GRAIL to offer the Galleri test, a multi-cancer early detection tool capable of identifying over 50 types of cancers, including those for which no standard screening exists (e.g., esophageal, pancreatic, ovarian, and liver). Recommended for adults at elevated cancer risk, particularly those aged 50 and older, this test detects cancer “fingerprints” before symptoms arise, offering a critical opportunity for early intervention.Dr. Mark Hyman, Co-Founder and Chief Medical Officer of Function Health, emphasized the importance of proactive health strategies: “With cancer risks rising, education, early detection, and research are crucial in combatting harmful diseases. By integrating the Galleri test into our platform, we’re enabling members to screen for cancer as part of their annual checkups, enhancing treatment options and outcomes.”Tackling a Growing Health CrisisCancer is projected to affect over two million individuals in the U.S